{"url_path":"/sec/rnac/8-k/2026-06-17/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1453687/0001453687-26-000090-index.html","accession_number":"0001453687-26-000090","cik":"0001453687","ticker":"RNAC","issuer_name":"Cartesian Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1453687/0001453687-26-000090-index.html","primary_entity_key":"0001453687","primary_entity_name":"Cartesian Therapeutics, Inc."},"word_count":359,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 12, 2026, Cartesian Therapeutics, Inc. (the “Company”) held the 2026 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 24,151,536 shares of the Company’s common stock, par value $0.0001 per share (the “common stock”), were present electronically or represented by proxy at the meeting, representing approximately 82.42% of the Company’s outstanding common stock as of the April 14, 2026 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Proxy Statement.\n\nProposal 1 - Election of three Class I Directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.\n\nNOMINEE\n\nVotes FOR\n\nVotes WITHHELD\n\nBroker Non-Votes\n\nMichael Singer, M.D., Ph.D.11,745,6198,083,5064,322,411\n\nTimothy A. Springer, Ph.D.18,665,1631,163,9624,322,411\n\nPatrick Zenner, M.B.A12,168,9197,660,2064,322,411\n\nBased on the votes set forth above, each director nominee was duly elected to serve until the Company’s 2029 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.\n\nProposal 2 - Approval, on a non-binding and advisory basis, of a resolution approving the compensation of the Company’s named executive officers.\n\nVotes FOR\n\nVotes AGAINST\n\nVotes ABSTAINED\n\nBroker Non-Votes\n\n13,659,709136,2176,033,1994,322,411\n\nBased on the votes set forth above, the stockholders approved, on a non-binding and advisory basis, a resolution approving the compensation of our named executive officers.\n\nProposal 3 - Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.\n\nVotes FOR\n\nVotes AGAINST\n\nVotes ABSTAINED\n\nBroker Non-Votes\n\n24,144,7426,157637—\n\nBased on the votes set forth above, the stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.\n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n CARTESIAN THERAPEUTICS, INC.\n\n  \n\n  \n\nDate: June 17, 2026By:/s/ Carsten Brunn, Ph.D.\n\n  Carsten Brunn, Ph.D.\n\n  President, Chief Executive Officer and Chairman of the Board"}